272
Participants
Start Date
December 22, 2016
Primary Completion Date
December 3, 2020
Study Completion Date
December 3, 2020
OLAPARIB
300 mg olaparib tablets taken orally twice daily
Research Site, New York
Research Site, New York
Research Site, New York
Research Site, The Bronx
Research Site, Pittsburgh
Research Site, Abington
Research Site, Philadelphia
Research Site, Newark
Research Site, Silver Spring
Research Site, Annandale
Research Site, Winston-Salem
Research Site, South Miami
Research Site, Germantown
Research Site, Cincinnati
Research Site, Detroit
Research Site, Detroit
Research Site, Milwaukee
Research Site, Saint Paul
Research Site, Minneapolis
Research Site, Skokie
Research Site, Shreveport
Research Site, Houston
Research Site, Aurora
Research Site, Los Angeles
Research Site, La Jolla
Research Site, Portland
Research Site, Anchorage
Research Site, Hartford
Research Site, New Haven
Research Site, Springfield
Research Site, Berkeley Heights
Research Site, Hackensack
Research Site, Newark
Research Site, Teaneck
Research Site, Providence
Research Site, Edmonton
Research Site, Vancouver
Research Site, Winnipeg
Research Site, Halifax
Research Site, Hamilton
Research Site, Kingston
Research Site, Mississauga
Research Site, Toronto
Research Site, Montreal
Research Site, Montreal
Research Site, Montreal
Research Site, Sherbrooke
Lead Sponsor
AstraZeneca
INDUSTRY